Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1HRD Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1

Interventions

pembrolizumab 30Nivolumab 12Carboplatin 6atezolizumab 5Trastuzumab 5aldesleukin 4Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4Cisplatin 4Bevacizumab 4spartalizumab 3fludarabine 3durvalumab 3Polymerase Chain Reaction 3Irinotecan 3Interleukin-2 3Gene Expression Profiling 3Blood Specimen Collection 3Biopsy 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2osimertinib 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × berzosertib × Thoracic × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡